Chronic obstructive pulmonary disease (COPD) is a chronic airway inflammatory disease characterised by airway obstruction. Aspergillus fumigatus sensitisation represents a distinct, clinically relevant endotype in COPD. In recent years, studies have shown that sensitised patients experience more frequent respiratory symptoms, exacerbations and a poorer prognosis, while the coexistence of allergic bronchopulmonary aspergillosis (ABPA) further increases morbidity and mortality. Recognising Aspergillus sensitisation (AS) as a potential treatable trait in COPD could provide new insights into disease heterogeneity and offer opportunities for personalised management. This review summarises the prevalence and clinical associations of AS among COPD patients.
Luo et al. (Fri,) studied this question.